Recently, many studies has shown several mechanisms associated with rapamycin resistance, which including promyelocytic leukemia (PML) gene [24], JAK2/STAT5 [25], Notch1 [26] and MAPK [27] mediated resistance to mTOR-targeted therapies in cancer. This evidence concerns the gene NOTCH1 and cancer.